Brixton Biosciences INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersCambridge, MA
SAM.gov UEIGAPRGK1TWAJ4
Brixton Biosciences develops Reneurx™ therapy, a nerve-selective treatment designed to provide pain control lasting up to six months from a single treatment. The product is currently investigational and has not been approved or cleared for marketing by the U.S. Food and Drug Administration.
Summarized from the company’s own website
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Brixton Biosciences INC | Cambridge | MA | — | LIKELY ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.